Huadong Medicine(000963.SZ): The clinical trial of injection HDM2012 has been approved.
East China Pharmaceutical (000963.SZ) announced that its wholly-owned subsidiary Hangzhou Sino-East China Pharmaceutical Co., Ltd. (referred to as "...
Huadong Medicine (000963.SZ) announced that its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (referred to as "Zhongmei Huadong") has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA). The application for the clinical trial of injectable HDM2012 (late-stage solid tumors) submitted by Zhongmei Huadong has been approved.
Related Articles
ZYLOXTB(02190) spent 85,500 Hong Kong dollars on July 18 to repurchase 4000 shares.
GF SEC (01776) completed the issuance of 1.4 billion yuan subordinate company bonds.
Northchip's life sciences board's IPO has been approved, focusing on precision diagnosis and treatment of cardiovascular diseases in Innovative Medical Management equipment production and research and sales.
ZYLOXTB(02190) spent 85,500 Hong Kong dollars on July 18 to repurchase 4000 shares.
GF SEC (01776) completed the issuance of 1.4 billion yuan subordinate company bonds.
Northchip's life sciences board's IPO has been approved, focusing on precision diagnosis and treatment of cardiovascular diseases in Innovative Medical Management equipment production and research and sales.
RECOMMEND
For the Third Consecutive Month, China Reduces U.S. Treasury Holdings by $900 Million in May, While Japan and the United Kingdom Increase Holdings
18/07/2025
Tariff-Driven Inflation Arrives with Delay as U.S. Consumers Begin to Feel the Initial Pinch
18/07/2025
Multiple Countries in High-Stakes Talks with the U.S.; EU Considers Invoking “Anti-Coercion Tool” as U.S. Plans Unified Tariffs on 150 Nations
18/07/2025
